Health & Fitness
Fri, November 18, 2011
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ ARIAD Pharmaceuticals, Inc. ] (NASDAQ: ARIA) today announced that interim clinical data from the fully enrolled, pivotal PACE trial of its investigational, pan-BCR-ABL inhibitor, [ ponatinib ], will be presented at the 53rd Annual Meeting of the American Society of Hematology (ASH) being held in San Diego, December 10-13, 2011. The interim findings from the PACE trial will be featured in an oral presentation on Sunday, December 11 and also will be highlighted in an investor meeting to be webcast live from San Diego. This trial is being conducted in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to either nilotinib or dasatinib, two currently available CML therapies, or those who have the T315I mutation of BCR-ABL for which no current treatments are known to be effective. Thirteen additional abstracts describing clinical and non-clinical work on ponatinib will also be presented at the meeting.
Oral Presentation of Interim Data from PACE Trial
| Title: | Initial Findings from the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation | |
| Oral Session: | Chronic Myeloid Leukemia a" Therapy: Resistance to Tyrosine Kinase Inhibitors | |
| Date & Time: | Sunday, December 11, 2011, 4:30 p.m. (PST) | |
| Abstract No.: | 109 | |
| Presenter: | Jorge E. Cortes, M.D. (The University of Texas MD Anderson Cancer Center) | |
| Location: | Ballroom 20BC |
Investor Meeting and Webcast
A breakfast meeting to review the interim PACE trial data with research analysts and institutional investors will feature Moshe Talpaz, M.D., Associate Director of Translational Research and Associate Chief of Hematologic Malignancies, Trotman Professor of Leukemia Research at the University of Michigan Medical Center, and members of ARIAD's management. Dr. Talpaz has been an investigator in the Phase 1 and Phase 2 trials of ponatinib. This meeting will be webcast live and can be accessed by visiting the investor relations section of the Companyas website at [ investor.ariad.com ] or dialing: 866.770.7125 (domestic) or 617.213.8066 (international) and providing the pass code 91497220.
| Date: | Monday, December 12, 2011 | |
| Time: | 7:00 a.m. to 8:00 a.m. (PST) | |
| Location: | The Westin Gaslamp Quarter Hotel, Santa Fe Conference Room |
To attend the meeting, please RSVP to [ Investor.breakfast@ariad.com ] by Wednesday, December 7, 2011.
A replay of this investor event will be available on the ARIAD website approximately three hours after the presentation and will be archived for four weeks. To ensure a timely connection to the live webcast, participants should log onto the webcast at least 15 minutes prior to the scheduled start time.
The following presentations are included among the 14 presentations at ASH to feature clinical and non-clinical data on ponatinib.
| Title: | Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies | |
| Oral Session: | Chronic Myeloid Leukemia a" Therapy: New Drugs, New Procedures | |
| Date & Time: | Monday, December 12, 2011, 3:00 p.m. (PST) | |
| Abstract No.: | 602 | |
| Presenter: | Jorge E. Cortes, M.D. (The University of Texas MD Anderson Cancer Center) | |
| Location: | Ballroom 20BC | |
| Title: | ATP Dependent Efflux Transporters ABCB1 and ABCG2 Are Unlikely to Impact the Efficacy, or Mediate Resistance to the Tyrosine Kinase Inhibitor, Ponatinib | |
| Poster Session: | Chronic Myeloid Leukemia a" Biology and Pathophysiology, Excluding Therapy: Poster II | |
| Date & Time: | Sunday, December 11, 2011, 6:00 a" 8:00 p.m. (PST) | |
| Abstract No.: | 2745 | |
| Presenter: | Deborah White, Ph.D. (University of Adelaide, Australia) | |
| Location: | Hall GH | |
| Title: | Ponatinib Is Active Against the CUX1-FGFR1 Fusion Kinase and Against Imatinib Resistance Mutations of the FIP1L1-PDGFR' Fusion Kinase and of KIT | |
| Poster Session: | Myeloproliferative Syndromes: Poster III | |
| Date & Time: | Monday, December 12, 2011, 6:00 a" 8:00 p.m. (PST) | |
| Abstract No.: | 3848 | |
| Presenter: | Els Lierman, Ph.D. (Center for Human Genetics, Katholieke Universiteit Leuven, Belgium) | |
| Location: | Hall GH | |
| Title: | Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutations | |
| Oral Session: | Molecular Pharmacology, Drug Resistance: Targeting Chemoresistant Cells and Niche | |
| Date & Time: | Tuesday, December 13, 2011, 8:45 a.m. (PST) | |
| Abstract No.: | 930 | |
| Presenter: | Catherine C. Smith, M.D. (The University of California San Francisco) | |
| Location: | Room 25 |
About ARIAD
ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIADas approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant and difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. For additional information, visit [ http://www.ariad.com ].
